Skip to content
Contact us
our pipeline

Ovarian Cancer

At HBC Immunology, our pipeline is built on the foundation of AI-optimized peptide therapeutics designed to overcome treatment resistance by restoring the tumor micro-environment. With a focus on ovarian cancer and prostate cancer, we are addressing the inevitable failure of frontline treatments, targeting root causes of resistance, and driving better outcomes for patients worldwide.
fram4245_an_image_with_tiles_of_older_female_patients_of_africa_a217d287-8dbd-4733-b9c4-c1659ecab2fd
WHY OVARIAN CANCER?

Understanding the Challenge

Ovarian cancer remains one of the most challenging cancers to treat, with a high mortality rate and limited effective therapies for advanced stages. In 2022 alone, there were 324,603 new cases and 206,956 deaths worldwide attributed to ovarian cancer. In the United States, projections for 2023 estimate 19,710 new diagnoses of Stage III/IV Platinum-Resistant Ovarian Cancer (PROC), with approximately 60% of these patients succumbing to the disease despite current treatment options.

Ovarian cancer presents an urgent unmet medical need due to its aggressive nature and the high rate of platinum-resistant cases. Addressing iron dysregulation represents a novel therapeutic approach to restoring treatment sensitivity and improving survival outcomes.

OUR APPROACH

The Role of Iron Metabolism in Treatment Resistance:

  • Platinum Resistance: Iron dysregulation is a critical driver of resistance to platinum-based chemotherapy, the current standard of care for ovarian cancer.
  • Tumor Progression: Dysregulated iron pathways allow cancer cells to evade treatment, contributing to disease progression and poor prognosis.
  • Therapeutic Challenge: Platinum-resistant ovarian cancer leaves few viable treatment options, resulting in high recurrence rates and limited survival outcomes.
fram4245_a_lab_bench_with_a_cyan_overlay_bd783fd8-7943-4220-9b25-069eb83145fc
Our lead candidate

FT-002a

FT-002a is our investigational AI-optimized peptide therapy designed to normalize iron metabolism in ovarian cancer cells and restore sensitivity to platinum-based chemotherapy in resistant tumors.

In Vitro Success:

FT-002a has shown promising results in human tissue assays, demonstrating the ability to reverse platinum resistance in ovarian cancer cells.

Iron Normalization:

FT-002a effectively targets iron dysregulation, reducing tumor free iron levels and restoring chemotherapy sensitivity.

 Oral Formulation Potential:

FT-002a's oral delivery mechanism offers a patient-friendly treatment option, enhancing accessibility and ease of administration.

Contact us to learn more.